Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04928677 · ClinicalTrials.gov registry record · Phase 1
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
A Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT04928677 is a Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT04928677, a Phase 1 study of Primary Extra-cranial Solid Tumor and Recurrent or Refractory Glypican 3 (GPC3), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
Conditions Studied
Interventions
- DRUG Codrituzumab
Study Locations (5)
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
Georgia
- Children's Healthcare of Atlanta (Data Collection Only) - Atlanta
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04928677
The ClinicalTrials.gov registry entry for NCT04928677 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Primary Extra-cranial Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Codrituzumab is the first listed.
NCT04928677 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04928677 about?
NCT04928677 is a clinical study titled "A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment". The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the...
What is the current status of trial NCT04928677?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-06-09. Estimated completion is 2027-06.
What conditions does trial NCT04928677 study?
This clinical trial studies the following conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3).
What interventions are being tested in trial NCT04928677?
The interventions under investigation include: Codrituzumab (DRUG).
Who is sponsoring clinical trial NCT04928677?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04928677 being conducted?
This trial has 5 study locations across California, Georgia, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Primary Extra-cranial Solid Tumor
All registered trials for this condition
Recurrent or Refractory Glypican 3 (GPC3)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.